Research Background In the tumor microenvironment, highly aggressive tumors evade immune system attacks by suppressing the cGAS-STING signaling pathway. The cGAS-STING pathway is a critical mechanism for cells to sense cytoplasmic double-stranded DNA and initiate immune responses. cGAS (cyclic GMP-AMP synthase) catalyzes the production of cGAMP upo...

Breast cancer is one of the most common malignant tumors among women worldwide, with a complex pathogenesis involving multiple gene mutations and signaling pathway abnormalities. Homologous Recombination Deficiency (HRD) is a significant molecular characteristic in breast cancer, closely related to patients’ sensitivity to PARP inhibitor (PARPi) th...

Academic Background Breast cancer is one of the most common cancers among women worldwide, particularly advanced or metastatic breast cancer, which is challenging to treat and has a poor prognosis. With the development of precision medicine, the role of molecular biomarkers in breast cancer treatment has become increasingly prominent. Circulating t...

Breast cancer is one of the most common malignancies among women worldwide. Although early intervention and appropriate treatment have significantly improved patient survival rates, approximately 30% of cases still experience recurrence and distant metastasis, resulting in a 5-year survival rate of less than 23%. Traditional clinical prediction met...

Breast cancer is one of the most common cancers among women worldwide, with over 56,000 women diagnosed annually in the UK. Despite advancements in treatment, approximately 40% of patients still undergo mastectomy. While mastectomy effectively controls cancer, it profoundly impacts patients’ quality of life. Many women describe mastectomy as a “dis...

Neoadjuvant Nivolumab and Chemotherapy in Early Estrogen Receptor-Positive Breast Cancer Academic Background Breast cancer is one of the most common cancers among women worldwide, with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer accounting for the majority of cases. Although ER+/HER2−...

Pembrolizumab Combined with Chemotherapy in High-Risk, Early-Stage ER+/HER2− Breast Cancer: A Randomized Phase 3 Trial Academic Background Breast cancer is one of the most common cancers among women worldwide, with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer accounting for a significant pro...

USP35 Promotes Breast Cancer Progression by Regulating PFK-1 Ubiquitination to Mediate Glycolysis Academic Background Breast cancer is the most common malignant tumor affecting women worldwide and remains a leading cause of cancer-related mortality among women. Despite the development of various treatment strategies for different molecular subtypes...

A Novel GLUT1-Targeted Fluorescence Imaging Tracer: Advances in Intraoperative Breast Cancer Detection Background and Problem Statement Breast cancer is one of the most common malignancies among women worldwide, with an estimated 2.3 million new cases and approximately 666,000 deaths globally in 2022. Surgical treatment for breast cancer typically ...

Enhancing Gene Delivery to Breast Cancer with Highly Efficient siRNA Loading and pH-Responsive Small Extracellular Vesicles Academic Background In recent years, small extracellular vesicles (sEVs) have become a hot topic in the field of drug delivery due to their natural origin and inherent homing properties. sEVs are lipid nanoparticles secreted b...